Literature DB >> 22192721

Left ventricular hypoplasia: a spectrum of disease involving the left ventricular outflow tract, aortic valve, and aorta.

Edward J Hickey1, Christopher A Caldarone, Brian W McCrindle.   

Abstract

"Hypoplastic left heart syndrome" is an unsatisfactory term describing lethal underdevelopment of the left ventricle (LV). It represents the more severe end of a spectrum of LV hypoplasia, mandating single-ventricle palliation or cardiac transplantation. Less severe "borderline" ventricular hypoplasia may instead allow various biventricular therapeutic strategies and better long-term outcomes. In this review, we consider factors causing and modifying the abnormal development of the LV. LV hypoplasia is typically seen in association with left ventricular outflow tract obstruction, itself part of a spectrum of related defects with common etiologies. Secondary responses to outflow obstruction are complex but involve abnormal flow dynamics and shear stresses that result in compromised and poorly orchestrated ventricular growth and development. Subsequent remodeling is likely influenced by genetic modifiers, including intrinsic myocardial growth signaling pathways, possibly including those of HAND transcription factors. In addition, during the latter stages of gestation, cardiomyocytes undergo a switch in myogenic potential and lose the ability to undergo mitosis. Ventricular hyperplasia can therefore no longer occur; remodeling is instead limited to muscular hypertrophy. Subtle differences in this switch in myogenic potential--and modulators thereof--are likely to be of clinical and therapeutic importance, especially in children with "borderline LVs" being considered for fetal interventions or post-natal biventricular repair strategies. Finally, by more clearly understanding the initiators and propagators of abnormal ventricular development, we can hope to lean away from grouping a heterogeneous group of infants together under the unsatisfactory term "hypoplastic left heart syndrome."
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22192721     DOI: 10.1016/j.jacc.2011.04.046

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  22 in total

Review 1.  Genetics in bicuspid aortic valve disease: Where are we?

Authors:  Katia Bravo-Jaimes; Siddharth K Prakash
Journal:  Prog Cardiovasc Dis       Date:  2020-06-27       Impact factor: 8.194

Review 2.  Clinical-pathological correlations of BAV and the attendant thoracic aortopathies. Part 2: Pluridisciplinary perspective on their genetic and molecular origins.

Authors:  Ares Pasipoularides
Journal:  J Mol Cell Cardiol       Date:  2019-06-06       Impact factor: 5.000

3.  Congenital heart disease linked to maternal autoimmunity against cardiac myosin.

Authors:  Charles R Cole; Katherine E Yutzey; Anoop K Brar; Lisa S Goessling; Sarah J Van Vickle-Chavez; Madeleine W Cunningham; Pirooz Eghtesady
Journal:  J Immunol       Date:  2014-03-26       Impact factor: 5.422

4.  Endocardial fibroelastosis is caused by aberrant endothelial to mesenchymal transition.

Authors:  Xingbo Xu; Ingeborg Friehs; Tachi Zhong Hu; Ivan Melnychenko; Björn Tampe; Fouzi Alnour; Maria Iascone; Raghu Kalluri; Michael Zeisberg; Pedro J Del Nido; Elisabeth M Zeisberg
Journal:  Circ Res       Date:  2015-01-13       Impact factor: 17.367

Review 5.  A roadmap to investigate the genetic basis of bicuspid aortic valve and its complications: insights from the International BAVCon (Bicuspid Aortic Valve Consortium).

Authors:  Siddharth K Prakash; Yohan Bossé; Jochen D Muehlschlegel; Hector I Michelena; Giuseppe Limongelli; Alessandro Della Corte; Francesca R Pluchinotta; Maria Giovanna Russo; Artur Evangelista; D Woodrow Benson; Simon C Body; Dianna M Milewicz
Journal:  J Am Coll Cardiol       Date:  2014-08-26       Impact factor: 24.094

6.  HAND1 loss-of-function within the embryonic myocardium reveals survivable congenital cardiac defects and adult heart failure.

Authors:  Beth A Firulli; Rajani M George; Jade Harkin; Kevin P Toolan; Hongyu Gao; Yunlong Liu; Wenjun Zhang; Loren J Field; Ying Liu; Weinian Shou; Ronald Mark Payne; Michael Rubart-von der Lohe; Anthony B Firulli
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

7.  De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies.

Authors:  Jason Homsy; Samir Zaidi; Yufeng Shen; James S Ware; Kaitlin E Samocha; Konrad J Karczewski; Steven R DePalma; David McKean; Hiroko Wakimoto; Josh Gorham; Sheng Chih Jin; John Deanfield; Alessandro Giardini; George A Porter; Richard Kim; Kaya Bilguvar; Francesc López-Giráldez; Irina Tikhonova; Shrikant Mane; Angela Romano-Adesman; Hongjian Qi; Badri Vardarajan; Lijiang Ma; Mark Daly; Amy E Roberts; Mark W Russell; Seema Mital; Jane W Newburger; J William Gaynor; Roger E Breitbart; Ivan Iossifov; Michael Ronemus; Stephan J Sanders; Jonathan R Kaltman; Jonathan G Seidman; Martina Brueckner; Bruce D Gelb; Elizabeth Goldmuntz; Richard P Lifton; Christine E Seidman; Wendy K Chung
Journal:  Science       Date:  2015-12-04       Impact factor: 47.728

8.  Genetic abnormalities in FOXP1 are associated with congenital heart defects.

Authors:  Sheng-Wei Chang; Mona Mislankar; Chaitali Misra; Nianyuan Huang; Daniel G Dajusta; Steven M Harrison; Kim L McBride; Linda A Baker; Vidu Garg
Journal:  Hum Mutat       Date:  2013-07-11       Impact factor: 4.878

9.  Left ventricular outflow tract obstruction following an uncomplicated primary percutaneous coronary intervention: a recognized but rare cause of cardiogenic shock.

Authors:  S Khan; Dp Ripley; Ma de Belder; At Goodwin; N Barham; Ra Wright
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-03

10.  Characterization of the vessel geometry, flow mechanics and wall shear stress in the great arteries of wildtype prenatal mouse.

Authors:  Choon Hwai Yap; Xiaoqin Liu; Kerem Pekkan
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.